Content continues after advertisement

IHC’z the Day

Clinician's Brief (Capsule)

Oncology

|October 2015

Sign in to Print/View PDF

Specialized testing for phenotyping of circulating atypical lymphocytes assists in differentiating leukemias. PCR for antigen receptor rearrangement (PARR) and flow cytometry have become common tests for referral centers. However, cost, time, and availability are concerns with these modalities. Immunocytochemistry (ICC) assists with identification of type of leukemia (B cell vs T cell) but is not considered as conclusive as immunohistochemistry (IHC). In this case series (2 dogs), formalin-fixed paraffin-embedded (FF-PE) blood clots were evaluated via IHC as an alternative to using PARR or flow cytometry for evaluating circulating lymphocyte neoplasia.

In Case 1, ICC on mesenteric lymph node aspirates failed to exhibit reactivity to lymphocyte markers, but IHC on the FF-PE blood clot obtained a few days later suggested a T-cell lymphoproliferative neoplasm, confirmed by PARR. In Case 2, ICC on liver aspirates, IHC on the FF-PE blood clot, and PARR were all in agreement for a T-cell phenotype. This initial data suggests the ability, even with atypical cell counts, to identify a T-cell phenotype, which may be a negative prognostic indicator. IHC on FF-PE blood clots provides a safe, minimally invasive, and inexpensive test alternative to more advanced diagnostic protocols. The stability of the sample allows for easy transport and retrospective evaluation. One potential limitation noted by the authors is potential overlap with nonneoplastic causes of lymphocytosis, such as in ehrlichiosis. Nevertheless, this methodology may provide an important tool in improved cancer therapy and warrants further investigation.

Commentary

Diagnostic testing for hematologic oncology cases is becoming more diverse. It started as primarily immunocytochemistry- and immunohistochemistry-driven options and has broadened into tests providing other means of assessing clonality and other aspects of cellular identity. Unfortunately, many of these tests take so long to return that they provide more of a background than a frontline for diagnosis. This paper provides an appealing, novel means of reaching a diagnosis. Importantly, it might be stretched to other neoplastic diseases (eg, mast cell neoplasia) in which multiple cells of a particular cell type are found in circulation. Further, it could provide unprecedented accessibility to advanced oncologic diagnostics not previously available in rural areas of the United States and other countries. Improved access raises the level of practice as a whole and may drive further innovation in the treatment of lymphoma and leukemia.—Ewan D. Wolff, PhD, DVM

References

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy